Peter A. Kaufman, MD

Articles by Peter A. Kaufman, MD

An expert on breast cancer presenting slides from a study

Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast Cancer

December 20th 2022

Peter A. Kaufman, MD, reviews data in patients with HER2+ metastatic breast cancer treated with tucatinib-based therapy.

Dr. Kaufman on Eribulin/ Capecitabine Side Effects

ByPeter A. Kaufman, MD

February 7th 2013

Peter A. Kaufman, MD, Associate Professor of Medicine at the Geisel School of Medicine at Dartmouth, discusses the side effect profiles of the microtubule inhibitor eribulin mesylate and the oral chemotherapeutic agent capecitabine.

Latest Updated Articles

Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast Cancer
December 20th 2022
Dr. Kaufman on Eribulin/ Capecitabine Side Effects
February 7th 2013

Peter A. Kaufman, MD

Articles by Peter A. Kaufman, MD

Patient Characteristics, Treatment Patterns, and Clinical Outcomes Associated With Tucatinib Therapy in HER2+ Metastatic Breast Cancer

Dr. Kaufman on Eribulin/ Capecitabine Side Effects

Latest Updated Articles

Trending on OncLive

FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults

Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer

Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma

Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer

Innovative Screening Approaches, Targeted Therapies, and Team-Based Care Drive Head and Neck Oncology Advances